Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: Effects on molecular targets

Molecular Cancer Therapeutics

Volumn 5, Issue 6, 2006, Pages 1530-1538

  Rao, Chinthalapally V ^a   Reddy, Bandaru S ^b   Steele, Vernon E ^c   Wang, C X ^b   Liu, Xiaoping ^d   Ouyang, Nengtai ^d   Patlolla, Jagan M R ^a   Simi, Barbara ^b   Kopelovich, Levy ^c   Rigas, Basil ^d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ARACHIDONIC ACID; AZOXYMETHANE; BETA CATENIN; CYCLINE; CYCLOOXYGENASE 2; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NCX 530; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; THROMBOXANE B2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER INCIDENCE; CANCER INHIBITION; COLON CANCER; COLON CARCINOGENESIS; COLON MUCOSA; COLON TUMOR; CONTROLLED STUDY; DIETARY INTAKE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL DESIGN; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RAT STRAIN; STRUCTURE ANALYSIS;

ACETATES; ANIMALS; ANTINEOPLASTIC AGENTS; ASPIRIN; AZOXYMETHANE; BETA CATENIN; CARCINOGENS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DIET; DINOPROSTONE; HUMANS; INDOLES; MALE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, INBRED F344;

EID: 33746061276     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0061     Document Type: Article

References (47)

1. American Cancer Society. Statistics for 2005. Atlanta (GA); American Cancer Society, 2005.
2. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
3. Baron JA, Cole BF, Sandier RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
4. Rayyan Y, Williams J, Rigas B. The role of NSAIDs in the prevention of colon cancer. Cancer Invest 2002;20:1002-11.
5. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 2004;10:324-30.
6. Kashfi K, Borgo S, Williams JL, et al. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther 2005;312:978-88.
7. Yeh RK, Chen J, Williams JL, et al. NO-donating nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 2004;67:2197-205.
8. Bak AW, McKnight W, Li P, et al. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sciences 1998;62:L 367-73.
9. Rao CV, Simi B, Cooma I, Rigas B, Kopelovich L, Reddy BS. Chemoprevention of colonic aberrant crypt foci by nitric oxide (NO) releasing NSAIDs. Abstract. Boston (MA); 2002.
10. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APE(Min/ +)) mice. Biochem Biophysics Res Common 2004;313:784-8.
11. Roberts J II, Morrow J. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment gout. In: Hardman JG, Limbird LE ('JG Hardman and LE Limbird) ('JG Hardman and LE Limbirds'), editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. p. 687-731.
12. Pozharisski KM. Pathology of tumors in laboratory animals. Tumors of the rat. Tumors of the intestines. IARC Sci Publ 1990;99:159-98.
13. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995;55:259-66.
14. Rao CV, Desai D, Rivenson A, Simi B, Amin S, Reddy BS. Chemoprevention of colon carcinogenesis by phenylethyl-3-methylcaffeate. Cancer Res 1995;55:2310-5.
15. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002;62:165-70.
16. Min/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proc Natl Acad Sci U S A 2005;102:4365-70.
17. Rao CV, Kawamori T, Hamid R, Reddy BS. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 1999;20:641-4.
18. Mann JR, DuBois RN. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J 2004;10:145-52.
19. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996;110:1259-62.
20. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
21. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterol 2003;124:600-7.
22. Shah V, Lyford G, Gores G, Farrugia G. Nitric oxide in gastrointestinal health and disease. Gastroenterology 2004;126:903-13.
23. Wallace JL, Del Soldato P. The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol 2003;17:11-20.
24. Iconomou G, Kalofonos HP, A.K. K, Vagenakis AG, Rigas B. A pilot study of NO-donating aspirin in patients with pancreatic cancer pain. J Support Oncol 2006;4:168.
25. Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res 2001;61:3285-9.
26. NCI Reports. NCI halts use of COX-2 inhibitor in large cancer prevention trial. NCI Bulletin 2005;2:1-2.
27. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004;4:29-42.
28. Rao CV, Rivenson R, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995;55:1464-72.
29. Reddy B, Rao C, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993;14:1493-7.
30. Nath N, Kashfi K, Chen J, Rigas B. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc Natl Acad Sci U S A 2003;100:12584-9.
31. Williams JL, Nath N, Chen J, et al. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 2003;63:7613-8.
32. Wallace JL, Ignarro LJ, Fiorucci S. Potential cardioprotective actions of NO-releasing aspirin. Nat Rev Drug Discov 2002;1:375-82.
33. Rao CV. Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 2004;555:107-19.
34. Corazzi T, Leone M, Maucci R, Corazzi L, Gresele P. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther 2005;315:1331-7.
35. Gao J, Kashfi K, Rigas B. In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. J Pharmacol Exp Ther 2005;312:989-97.
36. Carini M, Aldini G, Orioli M, Maffei Facino R. In vitro metabolism of a nitroderivative of acetylsalicylic acid (NCX4016) by rat liver: LC and LC-MS studies. J Pharm Biomed Anal 2002;29:1061-71.
37. Carini M, Aldini G, Orioli M, Piccoli A, Rossoni G, Maffei Facino R. Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat. Life Sci 2004;74:3291-305.
38. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
39. Spiegel A, Hundley TR, Chen J, et al. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochem Pharmacol 2005;70:993-1000.
40. Marnett LJ, Wright TL, Crews BC, Tannenbaum SR, Morrow JD. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem 2000;275:13427-30.
41. Salvemini D, Settle SL, Masferrer JL, Seibert K, Currie MG, Needleman P. Regulation of prostaglandin production by nitric oxide: an in vivo analysis. Br J Pharmacol 1995;114:1171-8.
42. Gupta RA, DuBois RN. Combinations for cancer prevention. Nat Med 2000;6:974-5.
43. Hao XP, Pretlow TG, Rao JS, Pretlow TP. Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 2001;61:8085-8.
44. Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 2002;296:1644-6.
45. Kashfi K, Ryan Y, Qiao LL, et al. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther 2002;303:1273-82.
46. Hundley TR, Rigas B. Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J Pharmacol Exp Ther 2006;316:25-34.
47. Gao J, Liu X, Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci U S A 2005;102:17207-12.